Researchers sought to evaluate the relationship between initiation of metformin and sulfonylurea therapy and clinical outcomes in patients with HF and diabetes.
Investigators assessed whether depressive symptoms, eating disorders, and health-related quality of life were related to a diagnosis of type 2 diabetes in youth and young adults.
Taking a 15- to 30-minute brisk walk can help break the cycle of β-cell inflammation that leads to hyperglycemia and development of type 2 diabetes in patients with post-acute COVID-19.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist primarily used to improve glycemic control in adults with type 2 diabetes. One favorable side effect of semaglutide is weight loss, and researchers have now studied its use in adults with overweight or obesity and without diabetes.
The investigators of a recent randomized trial examined the efficacy of sotagliflozin (a newer combined SGLT2/SGLT1 inhibitor) to prevent rehospitalization in people with diabetes discharged after acute heart failure exacerbations.
Type 2 diabetes and its complications are twice as high among Hispanics and Latinos than Whites, and some observers say there are differences in their care. Clinical Advisor interviewed Dr. A. Enrique Caballero, a leading expert in diabetic health in Latinos and Hispanics, about this subject.
A network meta-analysis was done to compare the effectiveness of SGLT2 inhibitors in participants with type 2 diabetes and cardiovascular risk factors.
Type 2 diabetes often goes into remission following weight loss after bariatric surgery. Researchers investigated whether greater amounts of weight loss were associated with higher rates of disease remission.
Study authors concluded that Diabetes Self-Management Education helps improve patient knowledge, glycemic control, and cholesterol levels in Black patients.
Investigators assessed the relationship among lean or fatty fish intake, fatty acid supplements, and lowered severity of type 2 diabetes in women following pregnancy.
People diagnosed with type 2 diabetes can eventually achieve normal glucose levels. But whether or when this means a person is “in remission” was the subject of an international group of experts convened by the American Diabetes Association.
Investigators assessed the effect of efpeglenatide, an exendin-based glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes at increased risk for cardiovascular events.
